Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Boston Scientific Partners with Omron for Atrial Fibrillation Management

Fineline Cube Nov 10, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at...

Company Deals

Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study

Fineline Cube Nov 10, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...

Company

BeiGene Reports 88% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings...

Company Deals

Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE

Fineline Cube Nov 9, 2022

A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...

Company Deals

Medtronic Partners with Shanghai JiaHui Hospital at CIIE

Fineline Cube Nov 9, 2022

US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled...

Company Deals

ChainGen Bio Raises RMB 45M in Angel Round for X-oligo Conjugates Development

Fineline Cube Nov 9, 2022

ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million...

Company Deals

Yibao Technology Secures Series A+ Funding to Expand Health Insurance Services

Fineline Cube Nov 9, 2022

Yibao Technology Co., Ltd, a Shanghai-based service provider for city-level supplementary commercial insurance (“Huiminbao”) schemes,...

Company Drug

Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain

Fineline Cube Nov 9, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...

Company Deals Digital

Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE

Fineline Cube Nov 9, 2022

Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th...

Company Drug

Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance

Fineline Cube Nov 9, 2022

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...

Company Drug

Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Seeks Public Feedback on New Drug Benefit-Risk Assessment Guidelines

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Releases Draft Guidelines on New Drug Benefit-Risk Assessment

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery

Fineline Cube Nov 9, 2022

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...

Policy / Regulatory

CDE Releases Guidelines on Pediatric Anti-tumor Drug Development

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released a Technical Guidelines document focused on “Clinical...

Company Deals

Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...

Company Deals

Pfizer China Partners with Alibaba Health for Disease Education at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership...

Posts pagination

1 … 558 559 560 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.